PL1912673T3 - Sposób przyłączania cząsteczek efektorowych do białek - Google Patents

Sposób przyłączania cząsteczek efektorowych do białek

Info

Publication number
PL1912673T3
PL1912673T3 PL06744294T PL06744294T PL1912673T3 PL 1912673 T3 PL1912673 T3 PL 1912673T3 PL 06744294 T PL06744294 T PL 06744294T PL 06744294 T PL06744294 T PL 06744294T PL 1912673 T3 PL1912673 T3 PL 1912673T3
Authority
PL
Poland
Prior art keywords
protein
effector molecules
proteins
attaching
cysteines
Prior art date
Application number
PL06744294T
Other languages
English (en)
Inventor
Sam Philip Heywood
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of PL1912673T3 publication Critical patent/PL1912673T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Catalysts (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
PL06744294T 2005-07-06 2006-06-29 Sposób przyłączania cząsteczek efektorowych do białek PL1912673T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0513852.4A GB0513852D0 (en) 2005-07-06 2005-07-06 Biological products
EP06744294A EP1912673B1 (en) 2005-07-06 2006-06-29 Process for attaching effector molecules to proteins
PCT/GB2006/002416 WO2007003898A1 (en) 2005-07-06 2006-06-29 Process for attaching effector molecules to proteins

Publications (1)

Publication Number Publication Date
PL1912673T3 true PL1912673T3 (pl) 2011-07-29

Family

ID=34856761

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06744294T PL1912673T3 (pl) 2005-07-06 2006-06-29 Sposób przyłączania cząsteczek efektorowych do białek

Country Status (15)

Country Link
US (1) US8378073B2 (pl)
EP (1) EP1912673B1 (pl)
JP (1) JP5203188B2 (pl)
CN (1) CN101212984B (pl)
AT (1) ATE502650T1 (pl)
AU (1) AU2006264684B2 (pl)
CA (1) CA2613481C (pl)
DE (1) DE602006020878D1 (pl)
DK (1) DK1912673T3 (pl)
ES (1) ES2361096T3 (pl)
GB (1) GB0513852D0 (pl)
PL (1) PL1912673T3 (pl)
PT (1) PT1912673E (pl)
SI (1) SI1912673T1 (pl)
WO (1) WO2007003898A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009205995B2 (en) * 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
HUE042114T2 (hu) 2009-02-17 2019-06-28 Ucb Biopharma Sprl Humán OX40-re specifikus ellenanyag-molekulák
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
US9623188B2 (en) 2011-07-07 2017-04-18 Novo Nordisk A/S Drug delivery injection pen with add-on dose capturing and display module
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
ES2869309T3 (es) 2013-12-13 2021-10-25 Novo Nordisk Healthcare Ag Método para la conjugación de proteínas con tioéter
CA3211226A1 (en) * 2014-02-11 2015-08-20 Seagen Inc. Selective reduction of proteins
GB201419184D0 (en) * 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising biomolecule-effector/reporter-conjugates using affinity resins
US10046058B2 (en) 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
IL252712B2 (en) * 2014-12-22 2024-04-01 UCB Biopharma SRL Method for protein production
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
CN107708679A (zh) 2015-06-04 2018-02-16 安特里阿比奥有限公司 用于制备位点特异性蛋白质偶联物的胺聚乙二醇化方法
KR102322530B1 (ko) * 2017-02-08 2021-11-05 화이자 인코포레이티드 캡핑된 및 비-캡핑된 항체 시스테인의 대규모 제조 공정 및 치료 단백질 접합에서의 그의 용도
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
AU2021395729A1 (en) 2020-12-07 2023-07-13 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
WO2022122652A1 (en) 2020-12-07 2022-06-16 UCB Biopharma SRL Antibodies against interleukin-22
BR112023022844A2 (pt) 2021-05-03 2024-01-23 UCB Biopharma SRL Anticorpos
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728430A (en) * 1986-02-10 1988-03-01 Millipore Corporation Diafiltration method
US5216183A (en) * 1988-04-19 1993-06-01 Teijin Limited Cyclopentanone/cyclopentenone derivative
US5225194A (en) * 1989-11-13 1993-07-06 Ldc Research Corporation Aqueous diafiltration process for preparing acellular vaccines, against selected bacterial diseases
AU1140495A (en) 1994-01-27 1995-08-03 Bristol-Myers Squibb Company Method for preparing thioether conjugates
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20040121415A1 (en) * 1996-12-10 2004-06-24 King David John Monovalent antibody fragments
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
DE69934248T2 (de) * 1998-10-30 2007-03-29 Nephros, Inc. Anlage zur nicht-isosmotischen diafiltration
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US6406631B1 (en) * 1999-07-30 2002-06-18 Nephros, Inc. Two stage diafiltration method and apparatus
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
CN1621091A (zh) * 2003-11-28 2005-06-01 付经国 聚乙二醇化轮状病毒体肠靶向制剂及其合成方法
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
US7908694B1 (en) * 2008-09-24 2011-03-22 Robert Sloane Mattress cover apparatus with integrated seals

Also Published As

Publication number Publication date
US20080306246A1 (en) 2008-12-11
CN101212984A (zh) 2008-07-02
CA2613481C (en) 2014-11-25
AU2006264684B2 (en) 2011-11-03
US8378073B2 (en) 2013-02-19
WO2007003898A1 (en) 2007-01-11
EP1912673A1 (en) 2008-04-23
AU2006264684A1 (en) 2007-01-11
PT1912673E (pt) 2011-04-14
JP2008544976A (ja) 2008-12-11
DE602006020878D1 (de) 2011-05-05
SI1912673T1 (sl) 2011-10-28
ATE502650T1 (de) 2011-04-15
CN101212984B (zh) 2011-09-28
CA2613481A1 (en) 2007-01-11
GB0513852D0 (en) 2005-08-10
ES2361096T3 (es) 2011-06-13
JP5203188B2 (ja) 2013-06-05
DK1912673T3 (da) 2011-05-02
EP1912673B1 (en) 2011-03-23
WO2007003898A8 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
PL1912673T3 (pl) Sposób przyłączania cząsteczek efektorowych do białek
CO6180433A2 (es) Moleculas de enlace de lingo y uso farmaceutico de las mismas
PL1951747T3 (pl) Sposób syntezy i związki pośrednie do syntezy kaspofunginy
HK1134283A1 (en) Arylsulfonamide compounds
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
ATE517917T1 (de) Herstellung eines rekombinanten il-18-bindenden proteins
MY160468A (en) Novel amino azaheterocyclic carboxamides
ATE496036T1 (de) Zwischenprodukte für die herstellung von pramipexol
BRPI0508628A (pt) conjugados de hidroxialquil amido e uma proteìna
ATE457310T1 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2007112940A3 (en) Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
EA201070510A1 (ru) Система, образованная пневматической шиной и гибким органом
TN2010000219A1 (en) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
ATE461934T1 (de) Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-car onsäure -lacton und schlüsselzwischenprodukte für dieses verfahren
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
EA200701852A1 (ru) Производные аминокислот
TW200740769A (en) Novel process
MX337358B (es) Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors
TW200738611A (en) 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
HK1107984A1 (en) Pyrrolopyridine-2-carboxylic acid amide derivativeuseful as inhibitor of glycogen phosphorylase
MX2007013872A (es) Procedimiento para la produccion de 4-bifenililazetidina-2-onas.
TW200716555A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
ATE458482T1 (de) Verwendung von amino substituierten benzimidazolen
WO2007144298A3 (de) Dispersionsfarbstoffe, ihre herstellung und ihre verwendung